An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug-Delivery Platform

摘要

The active targeting of drugs in a cell-, tissue-, or diseasespecific manner represents a potentially powerful technology with widespread applications in medicine, including the treatment of cancers. In a typical approach, a drug and a ligand are complementarily functionalized to allow for covalent or noncovalent (for example, biotin–streptavidin) conjugation for targeted delivery. The resulting chemical modifications of the drugs and/or the ligands may adversely affect the safety and efficacy profile of the drugs and the binding characteristics of the ligands, thereby resulting in less efficacious drug–ligand conjugates. It would be desirable to develop simple but effective targeted drug-delivery strategies that do not require chemical modification of the drug or the ligands.